

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** 10/28/1971  
**Gender:** Male  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 00/00/0000 00:00

**MGMT Promoter Methylation Detection by ddPCR**

ARUP test code 3005956

Block ID SMP24-3912 C1

**MGMT METH Result**

**Low Level** \*

This result has been reviewed and approved by Parisa Adelhardt, M.D.

Low level MGMT promoter methylation was detected.

**INTERPRETIVE INFORMATION:** MGMT Promoter Methylation Detection by ddPCR

**CHARACTERISTICS:** This assay is designed to detect MGMT promoter methylation. MGMT promoter methylation status is a prognostic biomarker in patients with high-grade gliomas and is useful in treatment decisions. For specific treatment recommendations, please refer to NCCN Clinical Practice Guidelines in Oncology for Central Nervous System Cancers (www.nccn.org).

**METHODOLOGY:** Genomic DNA is isolated from microscopically-guided dissection of tumor tissue followed by bisulfite conversion. Two droplet digital PCR reactions with conversion-specific primers and differentially labeled probes complementary to methylated and unmethylated MGMT promoter sequence are performed. Methylation status of CpG sites 75-78 is evaluated in reaction 1 and of CpG sites 79-82 in reaction 2. Percent methylation for each reaction is calculated as a ratio of methylated to all amplifiable alleles. The average percent methylation of both reactions is used for qualitative calls and reported as follows: average percent methylation of 0 to less than 5 percent is reported as "Not detected," 5 to less than 25 percent as "Low level," and equal or more than 25 percent as "Detected."

**LIMITATIONS:** Methylation at locations other than those listed above will not be detected.

**ANALYTICAL SENSITIVITY:** 5 percent methylation.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**MGMT METH Specimen**

Tissue

**H=High, L=Low, \*=Abnormal, C=Critical**

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Block ID	24-045-400804	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
MGMT METH Result	24-045-400804	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
MGMT METH Specimen	24-045-400804	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 24-045-400804  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 4 of 4 | Printed: 3/5/2024 7:47:58 AM  
4848